On November 17, 2026, the U.S. FDA granted accelerated approval to GSK's oral lung cancer drug Nelkarmi (neladalkib) for patients with advanced ALK-positive non-small cell lung cancer. Acquired through GSK's $10.6 billion buyout of Nuvalent, Nelkarmi is the UK drugmaker's second approved lung cancer treatment from the deal. Under CEO Luke Miels, GSK aims to rebuild its oncology portfolio to achieve £40 billion in annual revenue by 2031 and offset upcoming HIV patent expirations.
FDA approval details for Nelkarmi
- ▪Accelerated approval for GSK's Nelkarmi was based on clinical trial data showing anti-cancer activity and tumor shrinkage, including in patients whose cancer had spread to the brain
- ▪FDA granted accelerated approval to GSK's oral therapy neladalkib for ALK-positive non-small cell lung cancer after ALK tyrosine kinase inhibitors
Acquisition background and financial strategy
- ▪CEO Luke Miels said GSK acquired Nuvalent in part to help offset expected revenue losses from HIV medicines containing dolutegravir going off-patent starting in 2028
- ▪Prior to buying Nuvalent for $10.6 billion, GSK expanded its oncology portfolio through acquisitions including Tesaro for $5.1 billion in 2018 and Sierra Oncology for $1.9 billion in 2022
- ▪Nelkarmi is GSK's second commercial lung cancer drug acquired from its $10.6 billion acquisition of Nuvalent, following the July 2026 FDA approval of Jideytro
Competitive landscape and clinical trials
- ▪GSK is evaluating neladalkib directly against Roche's Alecensa in a late-stage clinical trial to assess its potential efficacy as a first-line lung cancer treatment
- ▪GSK's Nelkarmi will compete against established ALK-targeted lung cancer treatments including Roche's Alecensa and Pfizer's Lorbrena
Lung cancer demographics
- ▪GSK Chief Scientific Officer Tony Wood stated that patients suffering from ALK-positive lung cancer are often young and can remain on medication for years
- ▪According to the American Cancer Society, approximately 229,410 people in the United States are expected to be diagnosed with lung cancer in 2026
GSK oncology goals and revenue projections
- ▪Analysts surveyed by Bloomberg estimate that GSK's Nelkarmi could generate approximately $1 billion in annual sales by 2032
- ▪Jefferies analysts estimated that the lung cancer drug pipeline acquired by GSK from Nuvalent could yield between $5 billion and $7 billion in peak sales
- ▪Oncology products accounted for 6 percent of GSK's £33 billion in total revenues in 2025
Story comments
Loading comments…